Trojan horse” approach may enable ‘antigen-independent’ therapy with potential to treat cancers not traditionally amenable to immunotherapy.

Researchers sought to determine whether zanubrutinib combined with rituximab and lenalidomide would improve remission rates in older adults with newly diagnosed DLBCL.

The tumor microenvironment (TME) consists of mediators surrounding a tumor, including diverse cell types, blood vessels, and other cellular components. Certain elements of the TME can benefit patients ...

The complex tumor microenvironment (TME) in osteosarcoma is emerging as a critical factor in disease progression and treatment resistance. Recent insights highlight the intricate interplay between ...

MILAN — Is chronic lymphocytic leukemia (CLL) progression primarily driven by genetic mutations or by external cues from the tumor microenvironment? Despite major strides in targeted therapies, CLL ...

T cells dynamically adapt to signals in the TME, transitioning between effector, exhausted, and regulatory states. Cellular interactions, metabolic stress, and physical barriers (e.g., ECM) shape ...

The tumor microenvironment is not just a site of cancer growth—it is a high-stakes metabolic contest where tumor and immune cells vie for limited resources. Amino acids, once seen as passive nutrients ...

No tumor is an island. In the past two decades, it’s become increasingly appreciated that cancers are dependent on neighboring cells for their growth and survival. These tumor-friendly communities—or ...